<DOC>
	<DOCNO>NCT01010022</DOCNO>
	<brief_summary>The study shall evaluate efficacy safety two different hydroxyethyl starch solution ( artificial colloid 6 % HES130/0.4 6 % HES70/0.5 , Salinhes® ) intra-operative therapy hypovolemia maintenance circulate blood volume patient undergo orthopedic surgery . The primary efficacy endpoint require volume colloid solution infuse start end surgery . It aim clinical trial demonstrate comparable volume colloid solution use treatment group .</brief_summary>
	<brief_title>Trial 6 % HES130/0.4</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Hypovolemia</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Hydroxyethyl Starch Derivatives</mesh_term>
	<criteria>Patients expect blood loss ≥ 300 mL undergo elective orthopedic surgery Patients body weight ( BW ) ≥ 50 kg Known suspected allergy hydroxyethyl starch , include ingredient ( inclusive corn ) relate drug ASA classification ≥ IV Renal disease ( serum creatinine ≥ 2mg/dL ) Known bleed disorder Congestive heart failure Fluid overload Intracranial bleeding Severe hypernatremia Severe hyperchloremia</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>hypovolemia</keyword>
	<keyword>surgical blood loss</keyword>
	<keyword>orthopedic procedure</keyword>
	<keyword>Treatment reduce circulate blood volume ( hypovolemia ) include massive hemorrhage</keyword>
</DOC>